Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer
Publication Date: August 8, 2016
Key Points
Key Points
- Nearly 75% of women with ovarian cancer are diagnosed with advanced stage disease (International Federation of Gynecology and Obstetrics [FIGO] IIIC or IV) at presentation.
- Recently two randomized clinical trials (RCTs) demonstrated that neoadjuvant chemotherapy (NACT) was noninferior to primary cytoreductive surgery (PCS) with respect to progression-free and overall survival and resulted in a lower incidence of treatment-related morbidity and mortality.
- However, both trials have been criticized because the median overall survival, mean operative time, and rates of optimal cytoreduction were lower than expected.
- This Guideline provides guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.
Assessment
...sessment...
...women with suspected stage IIIC or...
...primary clinical evaluation should i...
Treatment
Treatme...
Table 1. Risk Factors for Perioperative M...
...o have a high perioperative risk profile...
...women are not eligible for medical...
...men who are fit for PCS, with potentially rese...
For women with a high likelihood of a...
...ho are fit for PCS but are deemed unlikely to hav...
...NACT is delivered, all patients shou...
...NACT, a platinum/taxane doublet is reco...
...ested surgery following three or four cycles o...
...h progressive disease on NACT have a poor p...
...Evaluation and Treatment of Women With S...